▶ 調査レポート

ジカウイルス検査の世界市場:診断検査種類別(分子検査、血清学的検査、PRNT)、エンドユーザー別、地域別分析

• 英文タイトル:Global Zika Virus Testing Market - Segmented by Diagnostic Test Type, End User, and Geography - Growth, Trends, and Forecast (2018 - 2023)
• レポートコード:B-MOR-06010
• 出版社/出版日: / 2018年6月20日
• レポート形態:英文、PDF、105ページ
• 納品方法:Eメール(受注後2営業日)
• 産業分類:医療・製薬
• 販売価格(消費税別)
  Single User(1名様用)¥471,750 (USD4,250)▷ お問い合わせ
  Team User(7名様用)¥499,500 (USD4,500)▷ お問い合わせ
  Corporate User¥971,250 (USD8,750)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、ジカウイルス検査の世界市場について調べ、ジカウイルス検査の世界規模、市場動向、市場環境、診断検査種類別分析、エンドユーザー別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、関連企業情報などをまとめた調査レポートです。
・イントロダクション
・エグゼクティブサマリー
・ジカウイルス検査の世界市場インサイト
・ジカウイルス検査の世界市場環境
・ジカウイルス検査の世界市場動向
・ジカウイルス検査の世界市場規模
・ジカウイルス検査の世界市場規模:診断検査種類別
・ジカウイルス検査の世界市場規模:エンドユーザー別
・ジカウイルス検査の世界市場:地域別市場規模・分析
・ジカウイルス検査の北米市場規模・予測
・ジカウイルス検査のアメリカ市場規模・予測
・ジカウイルス検査のヨーロッパ市場規模・予測
・ジカウイルス検査のアジア市場規模・予測
・関連企業情報・競争状況

The global Zika virus testing market is expected to register a CAGR of about 5.5%, during the forecast period of 2018-2023. Zika virus belongs to falvivirus genus transmitted by Ades mosquitoes. The market studied is primarily driven by the increasing R&D activities and rising prevalence of Zika virus infection. By region, due to well-developed healthcare infrastructure and rapid technological advancements by several biopharmaceutical companies in the testing of Zika virus, North America is expected to dominate the market studied.

Increasing Prevalence of Zika Virus Infection
Zika virus (ZIKV) infection has been known to be endemic in Africa and Southeast Asia. The consequent viral spread over the Pacific region led to an outbreak in the developed and emerging countries, worldwide. According to the World health Organization (WHO), about 84 countries/territories are or have been previously infected by ZIKV transmission. There have been major outbreaks of Zika virus infection during 2016-2017, in Asia-Pacific (particularly India) and South American countries. As per the Centers for Disease Control and Prevention, Mexico, South America, Central and Sub-Saharan African countries, and several countries in Southeast Asia are the major countries at risk for the growth of Zika virus infection. Thus, the rising prevalence of Zika virus infection in the emerging countries is one of the primary factors driving the growth of the market studied, over the forecast period.
The other prominent drivers of the market studied are – government initiatives to develop innovative tests, rising R&D efforts by biopharmaceutical companies, and technological advancements in medical diagnostic tests.

High Costs of Testing Kits
The high cost associated with the testing kits is one of the primary factors restricting the growth of the market studied. As per a recent article published in Becker’s Healthcare, the cost of screening is high and positive detections of Zika virus are low. As per the current US Food and Drug Administration (FDA) policy, blood sample from each donation is received individually, which leads to high costs. In the emerging markets like India, the cost is high, and in the range of about INR 4,500–INR 6,000 per test, in leading diagnostic centers, such as Dr. Lal PathLabs, SRL Diagnostics, Quest Diagnostics, and Star Imaging. Further, the laboratory diagnosis infection relies upon RNA in patient specimen and have lower limits of detection.
The other factor restricting the growth of the market studied is the sluggish adoption of new technologies in the emerging economies.

North America is Poised to Dominate
Due to the rising adoption of new technologies in the medical device sector, North America is expected to dominate the market studied. The growth can also be attributed to the rising awareness of the advantages of testing kits. The government organizations, such as CDC, Pan American Health Organization (PAHO), etc., have been mainly involved in the prevention of Zika virus infection. The CDC has received several funding over the past two years, to combat Zika outbreak across several territories. Several companies have been introducing their diagnostic tests, across North and South American countries.

Key Developments in the Market
• May 2018 – Roche received an FDA approval of a claim for the Cobas Zika test, for the use on the Cobas 6800/8800 systems, which streamlined the screening of multiple individual blood or plasma donations.
• February 2018 – The New York University College of Dentistry collaborated with Rheonix Inc., for the development of a novel test for Zika virus, which uses saliva to identify diagnostic markers of the virus.

Major Players: ABBOTT, ALTONA DIAGNOSTICS GMBH, CHEMBIO DIAGNOSTIC SYSTEMS INC., ELITECHGROUP, F. HOFFMANN-LA ROCHE LTD, FAST TRACK DIAGNOSTICS LTD, GENEKAM, LUMINEX CORPORATION, PRIMERDESIGN LTD, AND QUEST DIAGNOSTICS, amongst others.

Reasons to Purchase this Report
• Current and future Zika virus testing market outlook in the developed and emerging markets
• Analysis of various perspectives of the market, with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• The regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3 months analyst support, along with the Market Estimate sheet (in excel)

Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure that you to get a report that suits your needs.

レポート目次

1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry within the Industry
5.3 Pipeline Analysis
5.4 Regulatory Scenario
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Prevalence of Zika Virus Infection
6.1.2 Government Initiatives to Develop Innovative Tests
6.1.3 Increasing R&D by Biopharmaceutical Companies
6.1.4 Technological Advancements in Medical Diagnostics
6.2 Market Restraints
6.2.1 High Costs of Testing Kits
6.2.2 Sluggish Adoption of New Technologies in the Emerging Markets
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Diagnostic Test Type
7.1.1 Molecular Test
7.1.2 Serologic Test
7.1.3 Plaque Reduction Neutralization Test (PRNT)
7.2 By End User
7.2.1 Hospital/Clinic
7.2.2 Research/Diagnostics Laboratory
7.3 By Geography
7.3.1 North America
7.3.1.1 United States
7.3.1.2 Canada
7.3.1.3 Mexico
7.3.2 Europe
7.3.2.1 France
7.3.2.2 Germany
7.3.2.3 United Kingdom
7.3.2.4 Italy
7.3.2.5 Spain
7.3.2.6 Rest of Europe
7.3.3 Asia-Pacific
7.3.3.1 China
7.3.3.2 Japan
7.3.3.3 India
7.3.3.4 Australia
7.3.3.5 South Korea
7.3.3.6 Rest of Asia-Pacific
7.3.4 Middle East & Africa
7.3.4.1 GCC
7.3.4.2 South Africa
7.3.4.3 Rest of Middle East & Africa
7.3.5 South America
7.3.5.1 Brazil
7.3.5.2 Argentina
7.3.5.3 Rest of South America
8. Competitive Landscape
8.1 Merger and Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Product Launches
9. Key Players
9.1 Abbott
9.2 Altona Diagnostics GmbH
9.3 Chembio Diagnostic Systems Inc.
9.4 ELITechGroup
9.5 F. Hoffmann-La Roche Ltd
9.6 Fast Track Diagnostics Ltd
9.7 Genekam
9.8 Luminex Corporation
9.9 Primerdesign Ltd
9.10 Quest Diagnostics
* List Not Exhaustive
10. Future of the Market